NNBP Stock Overview
Nanobac Pharmaceuticals, Incorporated discovers and develops products and services to improve human health through the detection and treatment of calcifying nanoparticles (CNPs).
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
Nanobac Pharmaceuticals, Incorporated Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.000001 |
| 52 Week High | US$0.0001 |
| 52 Week Low | US$0.000001 |
| Beta | 0 |
| 1 Month Change | 0% |
| 3 Month Change | n/a |
| 1 Year Change | -99.00% |
| 3 Year Change | -99.94% |
| 5 Year Change | -99.92% |
| Change since IPO | -100.00% |
Recent News & Updates
Recent updates
Shareholder Returns
| NNBP | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 0% | -4.2% | -3.7% |
| 1Y | -99.0% | -2.0% | 20.5% |
Return vs Industry: NNBP underperformed the US Biotechs industry which returned -1.7% over the past year.
Return vs Market: NNBP underperformed the US Market which returned 20.2% over the past year.
Price Volatility
| NNBP volatility | |
|---|---|
| NNBP Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 11.5% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.4% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: NNBP has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine NNBP's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1994 | n/a | Jon Stanton | n/a |
Nanobac Pharmaceuticals, Incorporated discovers and develops products and services to improve human health through the detection and treatment of calcifying nanoparticles (CNPs). It manufactures and markets in vitro diagnostic (IVD) kits, such as assays, antibodies, and reagents for detecting CNPs. The company’s diagnostic assays comprise NANO-CAPTURE and NANO-SERO.
Nanobac Pharmaceuticals, Incorporated Fundamentals Summary
| NNBP fundamental statistics | |
|---|---|
| Market cap | US$249.00 |
| Earnings (TTM) | -US$6.58m |
| Revenue (TTM) | US$17.62k |
0.0x
P/S Ratio0.0x
P/E RatioIs NNBP overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| NNBP income statement (TTM) | |
|---|---|
| Revenue | US$17.62k |
| Cost of Revenue | US$14.52k |
| Gross Profit | US$3.10k |
| Other Expenses | US$6.58m |
| Earnings | -US$6.58m |
Last Reported Earnings
Dec 31, 2007
Next Earnings Date
n/a
| Earnings per share (EPS) | 0 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0.0% |
How did NNBP perform over the long term?
See historical performance and comparison